Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug
Tissue loading may occur at even lower rates of administration
*Per serve when prepared with water
Retatrutide is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors, currently under clinical evaluation for the management of obesity and type 2 diabetes
The liftHD applicator, now available to elevate treatment efficacy and patient throughput, further optimizes body contouring
